KinDex Pharmaceuticals
Signal active
Organization
Contact Information
Overview
KinDex Pharmaceuticals is a developer of novel therapeutics used to help patients suffering from metabolic disorders. It was established to focus on the discovery and development of molecules that improve women’s health and impact chronic disease. KinDex Pharmaceuticals is developing therapeutics that work through the Bitter Taste Receptors (TAS2Rs), a family of GPCR receptors that target inflammation and metabolic dysfunction.
About
Industries
Biotechnology, Health Care, Medical, Genetics
Founded
2009
Employees
1-10
Headquarters locations
Seattle, Washington, United States, North America
Social
Profile Resume
KinDex Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Genetics sector. The company focuses on Biotechnology and has secured $186.5M in funding across 32 round(s). With a team of 1-10 employees, KinDex Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - KinDex Pharmaceuticals, raised $5.5M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
2
Investors
3
Lead Investors
0
Total Funding Amount
$5.8M
Details
1
KinDex Pharmaceuticals has raised a total of $5.8M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2015 | Early Stage Venture | 5.5M |
Investors
KinDex Pharmaceuticals is funded by 4 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Polaris Partners | - | FUNDING ROUND - Polaris Partners | 5.5M |
| Jeff Katke | - | FUNDING ROUND - Jeff Katke | 5.5M |
| KinDex Pharmaceuticals | - | FUNDING ROUND - KinDex Pharmaceuticals | 5.5M |
| Jeffrey Bland | - | FUNDING ROUND - Jeffrey Bland | 5.5M |